Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Featured Expert Videos on Bipolar Depression and LATUDA

Watch these videos for important insights into bipolar depression and LATUDA

See a psychiatrist discuss the evaluation and treatment of bipolar depression.

Featured Content and Speakers


icon-video-moa
icon-video-moa

LATUDA Proposed Mechanism of Action

See how LATUDA is thought to work in relation to the brain neurotransmitters dopamine and serotonin. Although the mechanism of action (MOA) of LATUDA is unknown, this video presents a potential MOA for the treatment of bipolar depression.

See video

icon-video-mcintyre
icon-video-mcintyre

Dr. Roger S. McIntyre

Get information about bipolar depression from Dr. Roger S. McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.

See videos

icon-video-leblanc
icon-video-leblanc

Nurse Practitioner Tammy LeBlanc

Get insights into bipolar depression from a Nurse Practitioner perspective. Tammy LeBlanc, NP talks about bipolar disorder as well as collaborative care for patients with bipolar depression.

See videos

icon-video-jain
icon-video-jain

Dr. Rakesh Jain

Dr. Rakesh Jain, Clinical Professor in the Department of Psychiatry at Texas Tech University School of Medicine in Midland, Texas, discusses a case involving the evaluation and treatment of bipolar depression.

See video

icon-video-calabrese
icon-video-calabrese

Dr. Joseph R. Calabrese

The video series features discussions by Dr. Joseph R. Calabrese, an expert in the field of mood disorders. Watch as Dr. Calabrese talks about the challenges doctors face in diagnosing and treating patients with bipolar disorder, and then reviews specifics about LATUDA.

See videos

icon-video-barnes
icon-video-barnes

Nurse Practitioner Susan J. Barnes

Get an overview of the process of identifying, screening for, and diagnosing patients with bipolar disorder from the perspective of a psychiatric Nurse Practitioner, followed by a discussion of treating bipolar depression with LATUDA.

See video

icon-video-stahl
icon-video-stahl

Dr. Stephen M. Stahl

Dr. Stahl, Professor of Psychiatry, University of California, San Diego, shares his perspectives on bipolar depression, how it typically manifests, and the challenges of diagnosis.

See videos

Dr. Stephen M. Stahl
 
By the Book: Diagnosis of Bipolar Depression
Identifying Bipolar Depression is Challenging
Mixed Messages
Dr. Roger S. McIntyre
 
What is Bipolar Depression?
Nurse Practitioner Tammy LeBlanc
 
Is it Bipolar Disorder?
Collaborative Care
Dr. Rakesh Jain
 
A Case-Based Exploration of Identifying and Treating Bipolar Depression
Dr. Joseph R. Calabrese
 
Chapter 1: Bipolar Disorder Diagnosis and Treatment Challenges
Chapter 2: Study Design
Chapter 3: Efficacy
Chapter 4: Safety and Tolerability
Chapter 5: Metabolic Parameters
Chapter 6: Dosing
Interactive Journal Review: LATUDA for the Treatment of Bipolar Depression (full video)
Nurse Practitioner Susan J. Barnes
 
A Nurse Practitioner Approach to Diagnosis and Management of Bipolar Depression
LATUDA Proposed Mechanism of Action Video
 
See How LATUDA is Thought to Work

Featured experts are paid consultants of Sunovion.

Important Safety Information & Indications

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidality and Antidepressant Drugs
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior in patients over age 24. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LATUDA is not approved for use in pediatric patients with depression.

 

CONTRAINDICATIONS
LATUDA is contraindicated in the following:

WARNINGS AND PRECAUTIONS
Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

Tardive Dyskinesia (TD): TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

Metabolic Changes

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension, in patients with known cardiovascular disease or history of cerebrovascular disease and in patients who are antipsychotic-naїve.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer’s dementia).

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Suicide: The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS
Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

Indications

LATUDA is indicated for:

 

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warnings.